Group 1 - The core viewpoint of the news is that the Hong Kong Stock Connect innovative drug sector has rebounded, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising by 3.17% and achieving over 260 million yuan in real-time transactions [1][3] - The ETF covers 37 innovative drug companies, with 30 stocks showing gains, including a notable rise of over 8% for Sanofi and over 7% for InnoCare Pharma [1][3] - Pfizer has registered two global Phase III clinical trials for its PD-1/VEGF dual antibody PF-08634404, which is expected to become a cornerstone in global cancer treatment [1][3] Group 2 - The launch of the 2025 National Medical Insurance negotiation has introduced a "commercial insurance innovative drug catalog" mechanism, which is expected to alleviate the payment pressure for high-value innovative drugs through commercial insurance channels [1][3] - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which exclusively includes innovative drug development companies, with over 70% of its holdings in large-cap innovative drug leaders [5][6] - The index has shown a significant year-to-date increase of 108.14%, outperforming other innovative drug indices [6][7] Group 3 - The recent interest rate cut by the Federal Reserve is expected to enhance the valuation expansion probability of Hong Kong innovative drug assets, providing a favorable environment for financing and R&D investments in innovative drug companies [3] - The ETF has seen a net subscription of 48.61 million yuan recently, indicating strong investor interest despite the ETF hitting a three-month low [3][7] - The ETF has the largest scale and best liquidity among its peers, with a fund size of 1.806 billion yuan and an average daily transaction volume of 493 million yuan since its inception [7]
终于反弹！三生制药领衔，港股通创新药ETF（520880）放量涨超3%！国谈首次正式引入“商保创新药目录”机制